三阴性乳腺癌分子靶标的研究进展

Research progress in molecular targets of triple-negative breast cancer

三阴性乳腺癌对激素和HER-2靶向治疗均无应答,已成为乳腺癌临床治疗的一大挑战,迫切需要寻找对其治疗有效应答的新的分子靶标。本文综述三阴性乳腺癌分子靶标及其靶向治疗的最新研究进展。

Triple-negative breast cancer(TNBC) without estrogen receptor, progestrogen receptor and HER-2 expression, represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents. Therefore biomarkers predictive of response to treatment are of great importance in TNBC. This review evaluates biomarkers predictive of response to neoadjuvant chemotherapy and targeted therapies in TNBC, in order to increase opportunities to improve patient outcomes.